首页 | 本学科首页   官方微博 | 高级检索  
   检索      


KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Authors:Chiara Ambrogio  Jens Köhler  Zhi-Wei Zhou  Haiyun Wang  Raymond Paranal  Jiaqi Li  Marzia Capelletti  Cristina Caffarra  Shuai Li  Qi Lv  Sudershan Gondi  John C Hunter  Jia Lu  Roberto Chiarle  David Santamaría  Kenneth D Westover  Pasi A Jänne
Institution:1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA;2. Departments of Biochemistry and Radiation Oncology, the University of Texas Southwestern Medical Center, Dallas, TX 75390, USA;3. School of Life Science and Technology, Tongji University, 200092 Shanghai, China;4. Department of Pathology, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115, USA;5. Department of Molecular Biotechnology and Health Science, University of Torino, 10126, Italy;6. University of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, F-33600 Pessac, France;7. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA
Abstract:
/><ol class=
  • Download high-res image (275KB)
  • Download full-size image
  • Keywords:KRAS oncogene  wild-type allele  dimerization  lung adenocarcinoma  MAPK pathway  MEK inhibitors  allelic imbalance  drug resistance
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号